RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.

Int J Mol Sci · 2026 · PMC12841359 · PMID 41596492

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although siltuximab showed a trend toward delayed progression in high-risk SMM, the study did not meet its primary endpoint, suggesting a limited or modest effect of IL-6 blockade in this setting [ 93 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.